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Clostridium difﬁ  cile 
Infections among 
Hospitalized 
Children, United 
States, 1997–2006 
To the Editor: Zilberberg et 
al. described a notable increase in 
rates of Clostridium difﬁ  cile infec-
tion (CDI)–related hospitalizations of 
children during 1997–2006 on the ba-
sis of analysis of data from 2 national 
administrative databases (1). As the 
authors acknowledge, they used ad-
ministratively coded databases, which 
have inherent misclassiﬁ  cation  and 
testing biases.
Detection of C. difﬁ  cile toxin 
indicates that bowel ﬂ  ora have been 
perturbed. However, the clinical role 
of toxin detection or isolation of C. 
difﬁ  cile organisms in children is con-
troversial. Although primary CDI is a 
recognized pathologic entity in chil-
dren, one needs to consider whether 
another etiology related to a concomi-
tant infection, antimicrobial drug ad-
ministration, or alteration in enteral 
nutrition may be the precipitating 
event resulting in C. difﬁ  cile toxin 
production.
It is our clinical observation that 
availability of testing for C. difﬁ  cile 
and rapidity of assay results play a 
role in the submission of stool speci-
mens for analysis. In 2007, we con-
ducted a 5-month retrospective chart 
review of C. difﬁ  cile testing practices 
at 2 local tertiary-care pediatric hospi-
tals. Of 796 stool specimens submit-
ted, 42 (5%) were notable for the de-
tection of toxin A or B; these samples 
represented 35 patients (2). Medical 
coders likely face the same challeng-
es as clinicians who must interpret 
toxin assay results and their clinical 
role with regard to hospitalized chil-
dren. Although the ≈2-fold increase in 
CDI-associated hospitalization rates 
reported by Zilberberg et al. in their 
time series and cross-sectional analy-
ses is notable, these results should be 
interpreted within the context of clini-
cal and epidemiologic factors contrib-
uting to generation of this data.
Stephen M. Vindigni 
and Andi L. Shane
Author afﬁ  liation: Emory University School 
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In Response: I appreciate the let-
ter by Vindigni and Shane pointing 
out the need for a cautious approach to 
treatment for infection with Clostridi-
um difﬁ  cile isolated from the stool of 
children, given their propensity for 
colonization by this organism (1). I 
could not agree more. In our report, 
we noted an increase over time in the 
rate of hospitalizations for not only C. 
difﬁ  cile infections (CDIs) but also for 
rotavirus infections in children. This 
ﬁ  nding led us to acknowledge the pos-
sibility of a reporting bias for CDI (2). 
Other studies have detected a similar 
increase in CDIs among hospitalized 
children and have reported greater 
severity of associated disease (3–5). 
Such epidemiologic data, combined 
with emergence of the BI/NAP1/027 
hypervirulent strain of C. difﬁ  cile in 
the United States and abroad, support 
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a real increase in CDIs in a popula-
tion for which the clinical deﬁ  nition 
is likely less speciﬁ  c than for adults. 
Although a more precise clinical deﬁ  -
nition for CDI in children (primarily 
those <2 years of age) is needed, stud-
ies like ours, which are necessarily 
limited methodologically, can serve 
to alert clinicians to be more vigilant 
to the possibility of disease caused by 
this evolving pathogen, even in a pop-
ulation thought to be at low risk.
Marya D. Zilberberg 
Author afﬁ  liations: University of Massachu-
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